Activated Charcoal Arctium Lappa Root Bos Taurus C
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Activated Charcoal Arctium Lappa Root Bos Taurus C
- Multi-Ingredient Homeopathic Complex: Evaluation Not Feasible
Multi-Ingredient Homeopathic Complex: Evaluation Not Feasible
One-Sentence Summary
This candidate is a 25-ingredient complex mixture containing botanical extracts, animal-derived substances, homeopathic components, and trace minerals — most likely a homeopathic or complex natural preparation. The TxGNN model was unable to generate any repurposing predictions, as the pipeline could not map this multi-ingredient complex to a single DrugBank entity or knowledge graph node. With no clinical trial evidence, no literature linkage, and no regulatory record, meaningful evaluation cannot be completed at this stage.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — no regulatory approvals found |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (model prediction only — in this case, no prediction at all) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why No Prediction Was Generated
This formula contains 25 distinct components spanning multiple pharmacological categories:
Botanical / herbal ingredients: Arctium lappa root, Cinnamon, Fagus sylvatica flowering top, Gentiana lutea root, Lycopodium clavatum spore, Malus pumila flower, Prunus cerasifera flower, Rumex crispus root, Scrophularia nodosa whole, Syzygium cumini seed
Animal-derived components: Bos taurus colostrum, Oyster shell calcium carbonate, Pork intestine, Sus scrofa pancreas, Sus scrofa stomach
Mineral / elemental components: Copper gluconate, Gold, Magnesium gluconate, Manganese gluconate, Potassium gluconate
Homeopathic / reactive substances: Activated charcoal, Colchicum autumnale bulb, Nitric acid, Silver nitrate, Water
The TxGNN knowledge graph operates at the level of single chemical entities linked to DrugBank IDs. A 25-component mixture with no unified DrugBank identifier cannot be represented as a single node in the graph, making prediction structurally impossible with the current pipeline.
Notably, several individual components — such as Colchicum autumnale (source of colchicine) and Syzygium cumini (used in traditional diabetes management) — do have individual pharmacological profiles, but the combined formulation as a whole has no mappable identity in the current system.
Clinical Trial Evidence
Currently no related clinical trials registered for this multi-ingredient combination.
Literature Evidence
Currently no related literature available for this combination as a unified entity.
US Market Information
This product has no registered authorizations in the United States. The query returned zero records from the regulatory database.
Safety Considerations
Please refer to the package insert for safety information.
Note: One ingredient warrants specific attention even without a full safety assessment: Colchicum autumnale contains colchicine, which has a narrow therapeutic index and known toxicity at elevated doses (gastrointestinal toxicity, myelosuppression, neuromyopathy). If this product is to be evaluated further, the dose and bioavailability of colchicine-containing components must be clarified.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN pipeline was unable to generate any repurposing predictions because this 25-ingredient complex cannot be represented as a single knowledge graph entity. Without a prediction, there is no scientific basis to proceed with a repurposing evaluation under the current framework.
To proceed, the following is needed:
- Identify the product category: Confirm whether this is a homeopathic preparation, a dietary supplement, or a traditional medicine compound — each has a different regulatory pathway and evidence standard
- Decompose and evaluate individually: Run each pharmacologically active component (especially Colchicum autumnale, Syzygium cumini, Gentiana lutea) through TxGNN as standalone entities
- Obtain the original product labeling: Determine the intended indication, dosage, and manufacturer to establish a baseline
- Assess the colchicine risk: Quantify the colchicine content from Colchicum autumnale and determine whether it reaches pharmacologically active or toxic levels
- Reconsider pipeline scope: If this is a homeopathic product (sub-pharmacological dilutions), it falls outside TxGNN’s intended use case and should be routed to a different evaluation framework
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.